2023 World Conference on Lung Cancer (Posters)-EP07.05. Real-World Outcomes of Adjuvant Cisplatin/Vinorelbine vs Cisplatin/Pemetrexed in Resected Non-Squamous NSCLC

EP07.05. Real-World Outcomes of Adjuvant Cisplatin/Vinorelbine vs Cisplatin/Pemetrexed in Resected Non-Squamous NSCLC - PDF(Slides)

Back to course

Pdf Summary

This study analyzed the toxicities and dose intensity of adjuvant chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC). The analysis compared two treatment regimens: Cisplatin/Vinorelbine (Cis/Vin) and Cisplatin/Pemetrexed (Cis/Pem). The Cis/Pem group had fewer dose reductions, higher chemotherapy completion rates, and achieved a greater average dose intensity compared to the Cis/Vin group. Additionally, there were fewer hospitalizations and treatment visits per patient in the Cis/Pem group. The most common toxicities experienced were fatigue, constipation, and nausea, but there were no Grade 3-4 or hematological toxicities in the Cis/Pem group. The addition of granulocyte-colony stimulating factor (GCSF) to the Cis/Vin regimen resulted in a lower rate of neutropenia and fewer hospitalizations due to hematological toxicities. The Japanese JIPANG and European TREAT studies have also shown that Cis/Pem is a more tolerable treatment option with comparable outcomes to Cis/Vin. Scottish patients have struggled with the toxicity of Cis/Vin and achieved suboptimal dose intensities. The study center adopted a guideline change to use Cis/Pem instead of Cis/Vin, and primary prophylactic GCSF was given with Cis/Pem due to the COVID-19 pandemic. This change resulted in fewer dose reductions, hospitalizations, and better dose intensities. Overall, the study confirms that Cis/Pem is a more tolerable adjuvant regimen with the addition of GCSF. This change can reduce healthcare costs, relieve clinical service pressures, and improve treatment tolerability for patients.

Asset Subtitle

Samantha Low

Meta Tag

Speaker Samantha Low

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

adjuvant chemotherapy

NSCLC

Cisplatin/Vinorelbine

Cisplatin/Pemetrexed

dose intensity

chemotherapy completion rates

toxicities

hospitalizations

neutropenia

treatment tolerability